BioGenes will supply antibodies for the project, called cNeupro. The deal will enable it to share ownership of the antibodies and pocket royalties on the ones that lead to commercial products.
The study suggests it is "unlikely" that patents protecting biomedical inventions "will ever be licensed" if they have remained unlicensed for more than eight years since their priority patent application was filed.
Imperial College London and its spinout DNA Electronics have created a prototype for the so-called SNP Dr., which is being developed under a £1.2 million project that also includes Pfizer.
